Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Quince Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Quince Therapeutics, Inc.’s stock price such as:

• Quince Therapeutics, Inc.’s current stock price and volume
• Why Quince Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for QNCX from analysts
• QNCX’s stock price momentum as measured by its relative strength

About Quince Therapeutics, Inc. (QNCX)

Before we jump into Quince Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Want to learn more about Quince Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Quince Therapeutics, Inc..

Quince Therapeutics, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 12:05 PM, CST, Quince Therapeutics, Inc.’s stock price was $1.230.

Quince Therapeutics, Inc. is down 5.39% from its previous closing price of $1.300.

During the last market session, Quince Therapeutics, Inc.’s stock traded between $1.211 and $1.300. Currently, there are approximately 5.57 million shares outstanding for Quince Therapeutics, Inc..

Quince Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Quince Therapeutics, Inc. Stock Price History

Quince Therapeutics, Inc.’s (QNCX) price is currently down 6.11% so far this month.

During the month of May, Quince Therapeutics, Inc.’s stock price has reached a high of $1.340 and a low of $1.180.

Over the last year, Quince Therapeutics, Inc. has hit prices as high as $45.499 and as low as $0.800. Year to date, Quince Therapeutics, Inc.’s stock is down 96.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Quince Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded Quince Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Quince Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Quince Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Quince Therapeutics, Inc. (QNCX) by visiting AAII Stock Evaluator.

Relative Price Strength of Quince Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Quince Therapeutics, Inc. has a weighted four-quarter relative price strength of -16.80%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how Quince Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Quince Therapeutics, Inc. Stock Price: Bottom Line

As of May 8, 2026, Quince Therapeutics, Inc.’s stock price is $1.230, which is down 5.39% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Quince Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.